NewsSource: EClinCloud

Livestream Preview | eCOA Trends in the CNS Field and the Value of Rater Training

2 min readEClinCloud Editorial Team
Article image

Source: EClinCloud. Author: EClinCloud.

Article image

Live trailer

Livestream Preview


With rapid scientific and technological development and ongoing technological innovation, new treatments, assessment tools, and research advances continue to emerge in the central nervous system (CNS) field, placing higher demands on raters' professional capabilities and knowledge base.


To keep pace with these developments and raise the professional proficiency of raters across the industry, on January 29, 2024, from 19:00 to 20:00, EClinCloud and the CMAC DCT Alliance will jointly host the online livestream "eCOA Trends in the CNS Field and the Value of Rater Training". During the livestream, Su Quanyu, Co-Founder and Chief Commercial Officer of EClinCloud, will examine the latest eCOA trends in the CNS field and the innovation and application of rater training in the industry from a forward-looking perspective, and engage in interactive discussions with industry peers to jointly advance the development and progress of the industry.

Speaker

Su Quanyu

Co-Founder and Chief Commercial Officer, EClinCloud


He has extensive commercial and clinical project management experience across CROs and biotech companies, is a pioneer and practitioner in clinical trial digitalization, and is dedicated to advancing the industry's digital transformation.


Article image

Scan the QR code on the poster below to register for the livestream.


Article image





About EClinCloud

EClinCloud is a technology company focused on clinical research and development. It provides an integrated, interoperable all-in-one clinical trial cloud platform (across technology products and solutions including eCOA, CTMS, eTMF, EDC, RTSM, and RM, offering solutions such as scale design, scale copyright management, linguistic validation, rater training, and data quality analysis) as well as clinical trial endpoint assessment technologies across different therapeutic areas (including CNS and ophthalmology). Combining frontier technology with life science data, it aims to build a globally leading "patient-centric" SaaS cloud platform supporting clinical evidence, helping domestic and international pharmaceutical companies and research institutions improve research and development efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.






Article image


Read the original WeChat article

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.